What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Metabolic syndrome. Intervention: Time period (2009/2010) vs. Time period (1999/2000). Primary outcome: Age-adjusted prevalence of metabolic syndrome.

What question did this study set out to answer?

To evaluate national trends in the prevalence of metabolic syndrome, its five individual clinical components, and associated prescription drug usage in adults across a 10-year span.

September 14, 2026Journal of the American College of CardiologyOpen Access

Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999–2010

Q: What are the key findings of this study?

From 1999 to 2010, the age-adjusted prevalence of metabolic syndrome in US adults decreased from 25.5% to 22.9%, with varying trends in individual components.

View Full Paper

Ask AI

Bookmark

Key result

Metabolic syndrome prevalence in US adults declines to ~23% from 1999 to 2010.

Population

US adults (≥20 years) from the National Health and Nutrition Examination Survey (NHANES) from 1999–2010

Design

Cross-sectional

Authors

HBHiram Beltrán‐SánchezUniversity of California, Los Angeles MHMichael O. HarhayHeart Failure & Transplant MHMeera M. Harhay

Discussion

Member takes

Implication

While overall metabolic syndrome prevalence slightly decreased from 1999 to 2010 in the US, the prevalence of abdominal obesity and hyperglycemia increased, highlighting ongoing metabolic health challenges.

Key Points

To evaluate national trends in the prevalence of metabolic syndrome, its five individual clinical components, and associated prescription drug usage in adults across a 10-year span.
Analyzed biennial cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010 among adults aged 20 years and older.
Applied the 2009 Joint Scientific Statement criteria for metabolic syndrome: waist circumference (≥102 cm for males, ≥88 cm for females), fasting glucose ≥100 mg/dl, blood pressure ≥130/85 mm Hg, triglycerides ≥150 mg/dl, and low HDL-C (<40 mg/dl for males, <50 mg/dl for females), while evaluating prescription drug use.
Age-adjusted metabolic syndrome prevalence decreased from 25.5% (95% CI: 22.5–28.6) in 1999–2000 to 22.9% (95% CI: 20.3–25.5) in 2009–2010.
Hypertriglyceridemia declined from 33.5% to 24.3% and elevated blood pressure dropped from 32.3% to 24.0%, coinciding with higher utilization of lipid-modifying and antihypertensive agents.
Hyperglycemia increased from 12.9% to 19.9% and elevated waist circumference expanded from 45.4% to 56.1%, displaying substantial variations across sex and racial groups with notable increases in females.

Study Design

Type

Cross-Sectional

Structured PICO

Population

Adults aged ≥20 years from the US National Health and Nutrition Examination Survey (NHANES) evaluated between 1999 and 2010.

Outcome

Prevalence of metabolic syndrome (MetS), its five components, and their pharmacological treatment

Main Result

Absolute Event Rate: 22.9% vs 25.5%

Cite This Study

Beltrán‐Sánchez et al. (2013) conducted a cross-sectional in Metabolic syndrome. Time period (2009/2010) vs. Time period (1999/2000) was evaluated on Age-adjusted prevalence of metabolic syndrome. From 1999 to 2010, the age-adjusted prevalence of metabolic syndrome in US adults decreased from 25.5% to 22.9%, with varying trends in individual components.

synapsesocial.com/papers/6aa766ed0d2823f8ea00b466 https://doi.org/10.1016/j.jacc.2013.05.064

View Full Paper

Ask AI

Bookmark

Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999–2010

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999–2010

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider